ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Innovating alopecia treatment: nanostructured lipid carriers as advanced delivery platforms.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Lipid nanocarriers as innovative strategies for hair regrowth.Discover nano · 2026Review
- Nanotechnology in Dermatology: A Comprehensive Narrative Review of Performance, Safety, and Clinical Translation.Health science reports · 2026Article
- The Future of Alopecia Treatment: Plant Extracts, Nanocarriers, and 3D Bioprinting in Focus.Pharmaceutics · 2025Review
- Recent Advances in Drug Development for Hair Loss.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia, a common dermatological condition, poses significant psychological and social challenges. Despite the availability of various treatments, their efficacy is often limited by poor bioavailability and delivery challenges. Nanostructured lipid carriers have emerged as promising advanced drug delivery systems for alopecia treatment due to their ability to encapsulate both hydrophilic and lipophilic compounds, enhancing their stability, solubility, and controlled release. This manuscript explores the potential of Nanostructured lipid carriers as innovative delivery platforms for alopecia therapeutics, focusing on their formulation, characterization, and application in topical treatments. The unique properties of Nanostructured lipid carriers, including their small size, biocompatibility, and ability to target specific skin layers, are discussed in relation to improving the penetration and therapeutic efficacy of active ingredients such as minoxidil, finasteride, and plant-derived compounds. Additionally, we highlight the role of Nanostructured lipid carriers in improving scalp penetration, reducing side effects, and offering a more efficient alternative to conventional treatments. The manuscript concludes with insights into future trends, challenges, and the clinical potential of Nanostructured lipid carriers-based formulations in revolutionizing alopecia treatment.
Indexed as
Identifiers
39825967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.